A5028119831- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Cardiac pacing and defibrillation studies
- Cardiac electrophysiology and arrhythmias
- Blood Pressure and Hypertension Studies
- Cardiovascular Syncope and Autonomic Disorders
- ECG Monitoring and Analysis
- Cardiovascular Effects of Exercise
Martini Ziekenhuis
2020-2024
University Medical Center Groningen
2023-2024
University of Groningen
2021-2024
Atrial fibrillation (AF) progression is associated with adverse outcome, but the role of circadian or diurnal pattern AF onset remains unclear. We aim to assess association between time episodes clinical phenotype and in patients self-terminating AF.The Reappraisal AF: Interaction Between Hypercoagulability, Electrical Remodelling, Vascular Destabilization Progression study included who underwent extensive phenotyping at baseline continuous rhythm monitoring an implantable loop recorder...
Abstract Aims The recent 4S-AF (scheme proposed by the 2020 ESC AF guidelines to address stroke risk, symptom severity, severity of burden and substrate provide a structured phenotyping patients in clinical practice guide therapy assess prognosis) scheme has been as characterize with atrial fibrillation (AF). We aimed whether predicts progression self-terminating AF. Methods results analysed 341 included well-phenotyped Reappraisal Atrial Fibrillation: Interaction between HyperCoagulability,...
We hypothesize that in patients with paroxysmal atrial fibrillation (AF), verapamil is associated lower AF progression compared to beta blockers or no rate control.In this pre-specified post hoc analysis of the RACE 4 randomized trial, effect control medication on was analysed. Patients using Vaughan-Williams Class I III antiarrhythmic drugs were excluded. The primary outcome a composite first electrical cardioversion (ECV), chemical (CCV), ablation. Event rates are displayed Kaplan-Meier...
Long-term endurance exercise is suspect to elevate the risk of atrial fibrillation (AF), but little known about cardiovascular outcome and disease progression in this subgroup AF patients. We investigated whether previous level determines outcome.
Preventing high heart rates in patients with atrial fibrillation (AF) is a key objective of AF management. Data regarding paroxysmal (PAF) lacking. This analysis aimed to provide insight into during PAF episodes measured continuous implantable loop monitoring.
Objective Atrial fibrillation (AF) is associated with adverse events including conduction disturbances, ventricular arrhythmias and sudden death. The aim of this study was to examine brady- tachyarrhythmias using continuous rhythm monitoring in patients paroxysmal self-terminating AF (PAF). Methods In multicentre observational substudy the Reappraisal Fibrillation: interaction between hyperCoagulability, Electrical remodelling Vascular destabilisation progression (RACE V), we included 392...
Abstract Funding Acknowledgements Type of funding sources: None. Purpose To investigate whether there are differences between nondihydropyridine calcium channel blockers and beta on heart rate in patients with paroxysmal persistent atrial fibrillation (AF). Methods In present analysis the AFFIRM trial, effect control drugs was evaluated during first reported AF-episode as well last recorded sinus rhythm episode prior to AF. Patients who used both or switched AF were excluded. Results A total...
To investigate heart rate differences between non-dihydropyridine calcium channel blockers and beta-blockers in patients with non-permanent atrial fibrillation (AF).Using data from 'A Comparison of Rate Control Rhythm Patients Atrial Fibrillation' (AFFIRM), where were randomised 1:1 or rhythm control, we compared the effect control drugs on during AF as well sinus rhythm. Multivariable logistic regression was used to adjust for baseline characteristics.A total 4060 enrolled AFFIRM trial,...
Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main source(s): The Netherlands Cardiovascular Research Initiative: an initiative with support the Dutch Heart Foundation, and grant from Medtronic to institution. MHJPF was funded by a Karen Elise Jensen Foundation. JCN supported Novo Nordisk Foundation Background Atrial fibrillation (AF) has been associated adverse events constitutes significant, global healthcare challenge. Paucity exists on...
Abstract Background In patients with paroxysmal atrial fibrillation (PAF), verapamil reduces progression to persistent AF through its intracellular calcium-lowering effects. Little is known on the effects of beta-blockade. Methods this pre-specified post-hoc analysis RACE4 randomised trial (nurse-led care versus usual-care in newly detected AF) all PAF and treated beta-blockers or for rate control, were analyzed. Patients using class I III antiarrhythmic drugs excluded. The primary outcome...
Abstract Funding Acknowledgements Type of funding sources: Foundation. Main source(s): We acknowledge the support from Netherlands Cardiovascular Research Initiative: an initiative with Dutch Heart Foundation, CVON 2014-9: Reappraisal Atrial Fibrillation: interaction between hyperCoagulability, Electrical remodelling, and Vascular destabilisation in progression AF (RACE V). Unrestricted grant Medtronic Trading NL B.V. Background fibrillation (AF) is associated adverse outcome. The autonomic...
Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main source(s): support from the Netherlands Cardiovascular Research Initiative: an initiative with Dutch Heart Foundation, CVON 2014-9: Reappraisal Atrial Fibrillation: interaction between hyperCoagulability, Electrical remodelling, and Vascular destabilisation in progression AF (RACE V). Purpose To assess whether 4S-AF scheme predicts progression, cardiovascular hospitalizations mortality...